G1043
Guanfacine hydrochloride
≥98% (HPLC)
别名:
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H9Cl2N3O · HCl
化学文摘社编号:
分子量:
282.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
DGFYECXYGUIODH-UHFFFAOYSA-N
SMILES string
Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
InChI
1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
assay
≥98% (HPLC)
color
white
solubility
H2O: soluble 12 mg/mL at 60 °C
originator
Promius
Quality Level
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
正在寻找类似产品? 访问 产品对比指南
Application
Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.
Biochem/physiol Actions
α-2 noradrenergic receptor agonist.
Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.
Features and Benefits
This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Yuanyuan Li et al.
Bioanalysis, 3(22), 2501-2514 (2011-11-30)
Dried blood spot (DBS) technology was evaluated for the quantitative determination of guanfacine in human blood in clinical studies. A very sensitive DBS assay has been developed using HPLC coupled with an AB Sciex 5500 QTRAP® (Applied Biosystems/MDS Sciex, ON
Sandra Bond Chapman et al.
The journals of gerontology. Series A, Biological sciences and medical sciences, 67(7), 773-780 (2012-05-10)
Human cognitive aging has been too long neglected and underappreciated for its critical importance to quality of life in old age. The articles in this session present novel approaches to improving cognitive function in normal aging persons with drugs and
Helen C Fox et al.
Journal of psychopharmacology (Oxford, England), 26(7), 958-972 (2012-01-12)
Cocaine dependence is associated with increased stress and drug cue-induced craving and physiological arousal but decreased prefrontal activity to emotional and cognitive challenge. As these changes are associated with relapse risk, we investigated the effects of α2 receptor agonist guanfacine
Tamara Pringsheim et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 57(3), 133-143 (2012-03-09)
This article seeks to provide the practising clinician with guidance on the pharmacological management of tic disorders in children and adults. We performed a systematic review of the literature on the treatment of tic disorders. A multi-institutional group of 14
Floyd R Sallee et al.
Journal of child and adolescent psychopharmacology, 22(3), 206-214 (2012-05-23)
Extended-release guanfacine (GXR) is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years. This post-hoc analysis further examines the effects of GXR on hyperactivity-impulsivity and inattentiveness. Data from two large double-blind placebo-controlled pivotal trials
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持